在试点和可行性研究中共同评估多个终点
Robert N Montgomery1, Amy E Bodde2, Eric D Vidoni3
1Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, USA.
Statistical methods in medical research
|February 12, 2025
概括
本研究引入了一种新的联合可行性空间 (JFS) 方法,用于试点和可行性研究. 这种方法通过更有效地分析多个终点来改善对未来试验可行性的评估.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 医疗保健服务研究 医疗服务研究
背景情况:
- 试点和可行性研究对于确定最终试验的可行性至关重要.
- 目前用于评估可行性终点的方法通常是简单的,并且没有充分考虑未来的试验要求.
研究的目的:
- 提出和评估一种新的统计方法,用于分析试点研究中的可行性结果.
- 通过结合多个终点和未来的研究设计,加强对未来试验可行性的评估.
主要方法:
- 共同可行性空间 (JFS) 的开发,以定义表明未来试验可行性的结果组合.
- 使用贝叶斯方法估计实现联合可行性的概率.
- 模拟研究以创建基于频客运营特征和与现有方法的比较的决策规则.
主要成果:
- 提出的方法有效地结合了多个可行性终点之间的关系.
- 新方法的表现与单个终点的现有方法具有可比性.
- 与通用方法相比,该方法在分析多个可行性终点时显示出更高的效率.
结论:
- 可行性终点是试点和可行性研究的核心,需要更严格的分析.
- 开发的联合可行性空间 (JFS) 方法为评估未来临床试验的可行性提供了更有效和高效的方法.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
114
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
114
01:24Kaplan-Meier Approach
80
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
80